Inhibition of T cell cAMP formation by cyclosporin A and FK506

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 353, Issue 5, 1996, Pages 513-516

  Ockenfels, Hans M ^a   Wagner, Stephan N ^a   Oeljeklaus, Petra ^a   Schneck, Birgit ^a   Nußbaum, Gregor ^a   Jakobs, Karl H ^a   Goos, Manfred ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cyclic AMP; Cyclosporin A; FK506; Psoriasis; T cells

Indexed keywords

CYCLIC AMP; CYCLOSPORIN A; FORSKOLIN; IMMUNOSUPPRESSIVE AGENT; ISOPRENALINE; PROPRANOLOL; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HUMAN; HUMAN CELL; MALE; PSORIASIS; REGULATORY MECHANISM; T LYMPHOCYTE;

EID: 0029928035     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00169170     Document Type: Article

References (18)

1. Baker BS, Fry L (1992) The immunology of psoriasis. Br J Dermatol 126:1-9
2. + immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. Arch Dermatol Res 286:87-96
3. Bøyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 [Suppl]:77-89
4. Cameron AM, Steiner JP, Sabatini DM, Kaplin AI, Walensky LD, Snyder SH (1995a) Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proc Natl Acad Sci USA 92:1784-1788
5. 2+ flux. Cell 83:463-472
6. Duncan JI (1994) Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J Invest Dermatol 102:84-88
7. Eedy DJ, Canavan JP, Shaw C, Trimble ER (1990) Beta-adrenergic stimulation of cAMP is defective in cultured dermal fibroblasts of psoriatic subjects. Br J Dermatol 122:477-483
8. Erlanger BF (1992) Do we know the site of action of cyclosporin? Immunol Today 13:487-489
9. Green H (1978) Cyclic AMP in relation to proliferation of the epidermal cell: a new view. Cell 15:801-811
10. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Erdjument-Bromage H, Tempst P, Marks AR (1992) FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 267:9474-9477
11. Liu J (1993) FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 14:290-295
12. Ockenfels HM, Nußbaum G, Oeljeklaus P, Schultewolter T, Haen E, Burger PM, Goos M (1994) Drugs that provoke psoriasis vulgaris and those used in its therapy alter the phosphotyrosine content and also the cAMP level of T-cells. Arch Dermatol Res 286:179-180
13. Powles AV, Baker BS, Fry L (1989) Cyclosporin and skin disease. In: Thomson AW (ed) Cyclosporin: mode of action and clinical application. Kluwer Academic Publishers, Dordrecht, pp 191-212
14. Schreiber SL, Crabtree GR (1992) The mechanisms of action of cyclosporin A and FK506. Immunol Today 13:136-142
15. Sugiyama H, Chen P, Hunter M, Taffs R, Sitkovsky M (1992) The dual role of the cAMP-dependent protein kinase Ca subunit in T-cell receptor-triggered T-lymphocytes effector functions. J Biol Chem 267:25256-25263
16. Voorhees JJ, Duell EA, Stawiski M, Harrell ER (1974) Cyclic nucleotide metabolism in normal and proliferating epidermis. Adv Cycl Nucl Res 4:117-162
17. Walsh CT, Zydowsky LD, McKeon FD (1992) Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 267:13115-13118
18. Won Y-H, Sauder DN, McKenzie RC (1994) Cyclosporin A inhibits keratinocyte cytokine gene expression. Br J Dermatol 130:312-319